Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-05), Caliway Biopharmaceuticals Co's 3-1 Month Momentum % is 12.03%.
The industry rank for Caliway Biopharmaceuticals Co's 3-1 Month Momentum % or its related term are showing as below:
TPE:6919's 3-1 Month Momentum % is ranked better than 81.83% of 1387
companies
in the Biotechnology industry
Industry Median: -5.77
vs TPE:6919: 12.03
Caliway Biopharmaceuticals Co (TPE:6919) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Caliway Biopharmaceuticals Co 3-1 Month Momentum % Related Terms
TPE:6919 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliway Biopharmaceuticals Co 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Caliway Biopharmaceuticals Co's 3-1 Month Momentum % falls into.
Caliway Biopharmaceuticals Co (TPE:6919) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliway Biopharmaceuticals Co (TPE:6919) has a 3-1 Month Momentum % of 12.03% as of Sep. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Caliway Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Caliway Biopharmaceuticals Co ranks #252 out of 1387 companies in the Biotechnology industry, placing it in the top 18.2%.
Is Caliway Biopharmaceuticals Co's 3-1 Month Momentum % too high?
Caliway Biopharmaceuticals Co's current 3-1 Month Momentum % is 12.03%. Based on the distribution chart, Caliway Biopharmaceuticals Co ranks #252 out of 1387 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Caliway Biopharmaceuticals Co ranks #252 out of 1387 companies for 3-1 Month Momentum %. This places Caliway Biopharmaceuticals Co in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Caliway Biopharmaceuticals Co and its competitors. Caliway Biopharmaceuticals Co's current 3-1 Month Momentum % is 12.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.13, compared to a current price of NT$86.40 — trading 46.1% above its estimated fair value. The current 3-1 Month Momentum % is 12.03%. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current 3-1 Month Momentum % is 12.03% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of NT$86.40 is trading 46.1% above its estimated GF Value™ of NT$59.13.
GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for TPE:6919:
3-1 Month Momentum %: 12.03%
GF Value™: NT$59.13 vs. price of NT$86.40 (46.1% above fair value)
No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score
Get the complete analysis for TPE:6919
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6919 has been successfully added to your 
